Variables | Univariate | Multivariate | ||
Hazard Ratio (95% CI) p-value | Hazard Ratio (95% CI) p-value | |||
Age ≥ 65 y (vs. <65 y) | 1.248 (0.849 - 1.834) | 0.259 |
|
|
Male gender (Y/N) | 0.897 (0.611 - 1.318) | 0.581 |
|
|
MPO-ANCA (vs. PR3-ANCA) | 1.155 (0.583 - 2.286) | 0.679 |
|
|
General manifestation (Y/N) | 0.796 (0.537 - 1.182) | 0.258 |
|
|
ENT involvement (Y/N) | 0.628 (0.199 - 1.979) | 0.427 |
|
|
Cardiovascular involvement (Y/N) | 2.575 (1.757 - 3.774) | <0.001 | 1.174 (0.783 - 1.760) | 0.438 |
Abdominal involvement (Y/N) | 3.291 (2.241 - 4.833) | <0.001 | 1.415 (0.910 - 2.199) | 0.123 |
Nervous system involvement (Y/N) | 1.214 (0.692 - 2.131) | 0.499 |
|
|
Pulmonary involvement (Y/N) | 1.284 (0.877 - 1.881) | 0.199 |
|
|
ILD (Y/N) | 1.126 (0.746 - 1.700) | 0.571 |
|
|
Hematuria or Proteinuria | 1.894 (1.127 - 3.183) | 0.016 | 1.027 (0.596 - 1.770) | 0.922 |
Alveolar hemorrhage | 1.492 (0.917 - 2.427) | 0.107 |
|
|
SCR ≥ 500 μmol/L (vs. <500 μmol/L) | 20.935 (12.266 - 35.732) | <0.001 | 13.583 (7.646 - 24.128) | <0.001 |
C3 ≤ 0.8 g/L (vs. >0.8 g/L) | 1.769 (1.193 - 2.625) | 0.005 | 1.506 (1.001 - 2.264) | 0.049 |
Hemoglobin ≤ 90 g/L (vs. >90 g/L) | 2.836 (1.882 - 4.274) | <0.001 | 1.090 (0.698 - 1.701) | 0.705 |
ALB < 30 g/L (vs. ≥30 g/L) | 1.070 (0.729 - 1.570) | 0.731 |
|
|
BVAS ≥ 15 (vs. <15) | 3.577 (2.391 - 5.351) | <0.001 | 1.660 (1.083 - 2.543) | 0.020 |
Immunosuppressive treatment (Y/N) | 0.314 (0.211 - 0.467) | <0.001 | 0.523 (0.340 - 0.803) | 0.003 |